- One of the largest biologics clinical manufacturing facilities globally with 6 production lines which enable WuXi Biologics to complete 60 IND-enabling projects per year
SHANGHAI, July 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the first GMP campaign in the new MFG3 facility was completed successfully.
This 200,000 sq. ft. newly completed state-of-the-art clinical manufacturing facility includes process development labs and 6 production lines: 2 x 2,000L fed-batch, 1 x 1,000L fed-batch and 1 x 200L fed-batch, 1 x 1,000L perfusion and 1 x 500L perfusion. The flexible design can handle production from 50L-2,000L scale fed-batch production and 125L-1,000L scale perfusion production. In addition, the facility includes both traditional fed-batch operations and new continuous perfusion suites coupled with continuous purification, one of the first next-generation manufacturing platforms to be implemented in the global biologics industry. With this addition, WuXi Biologics boosts the largest mammalian cell culture capacity in China with total bioreactor capacity of approximately 43,000L and can run 10 GMP campaigns of different products ranging from 50L-12,000L scale at the same time.
"We are continuing to expand our capacity to enable global partners and expedite biologics development. With this newly added capacity, WuXi Biologics will be able to enable 60 IND projects and 3 BLA projects per year, which showcases our unparalleled capacities," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "With globally recognized technical capabilities and unparalleled capacities, we are transforming how biologics are developed and manufactured globally."
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of the end of 2017, there were a total of 161 integrated projects, including 90 projects in pre-clinical development stage, 62 projects in early-phase (phase I and II) clinical development, 8 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
